Displaying One Session

View

AstraZeneca - Improving outcomes with immuno-oncology: Evolving treatment paradigms for first-line ES-SCLC and unresectable Stage III NSCLC (ID 49)

Time
12:00 - 13:30

Welcome and introduction (ID 1294)

Emerging immuno-oncology treatment strategies for first-line ES-SCLC (ID 1295)

Treating ES-SCLC using immuno-oncology: A clinical case study (ID 1296)

The treatment paradigm for unresectable stage III NSCLC: recent clinical advances with immuno-oncology (ID 1297)

Treating unresectable Stage III NSCLC using immuno-oncology: A clinical case study (ID 1298)

Audience Q&A (ID 1299)